Nyxoah (NYXH) Competitors $6.28 +0.11 (+1.78%) Closing price 04:00 PM EasternExtended Trading$6.26 -0.03 (-0.40%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NYXH vs. EMBC, TNDM, AXGN, BBNX, SIBN, BVS, AVNS, ZIMV, KIDS, and TMCIShould you be buying Nyxoah stock or one of its competitors? The main competitors of Nyxoah include Embecta (EMBC), Tandem Diabetes Care (TNDM), AxoGen (AXGN), Beta Bionics (BBNX), SiBone (SIBN), Bioventus (BVS), AVANOS MEDICAL (AVNS), ZimVie (ZIMV), OrthoPediatrics (KIDS), and Treace Medical Concepts (TMCI). These companies are all part of the "medical equipment" industry. Nyxoah vs. Its Competitors Embecta Tandem Diabetes Care AxoGen Beta Bionics SiBone Bioventus AVANOS MEDICAL ZimVie OrthoPediatrics Treace Medical Concepts Nyxoah (NASDAQ:NYXH) and Embecta (NASDAQ:EMBC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability. Do analysts prefer NYXH or EMBC? Nyxoah currently has a consensus target price of $15.00, suggesting a potential upside of 138.85%. Embecta has a consensus target price of $19.00, suggesting a potential upside of 31.22%. Given Nyxoah's stronger consensus rating and higher probable upside, research analysts clearly believe Nyxoah is more favorable than Embecta.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nyxoah 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Embecta 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.75 Which has more risk & volatility, NYXH or EMBC? Nyxoah has a beta of 1.61, meaning that its share price is 61% more volatile than the S&P 500. Comparatively, Embecta has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. Does the media refer more to NYXH or EMBC? In the previous week, Embecta had 7 more articles in the media than Nyxoah. MarketBeat recorded 13 mentions for Embecta and 6 mentions for Nyxoah. Embecta's average media sentiment score of 1.41 beat Nyxoah's score of -0.17 indicating that Embecta is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nyxoah 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Embecta 8 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings & valuation, NYXH or EMBC? Embecta has higher revenue and earnings than Nyxoah. Nyxoah is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNyxoah$4.89M43.74-$64.10M-$2.30-2.73Embecta$1.12B0.75$78.30M$1.4310.13 Is NYXH or EMBC more profitable? Embecta has a net margin of 7.58% compared to Nyxoah's net margin of -1,541.84%. Embecta's return on equity of -23.40% beat Nyxoah's return on equity.Company Net Margins Return on Equity Return on Assets Nyxoah-1,541.84% -79.18% -54.92% Embecta 7.58%-23.40%14.46% Do institutionals & insiders hold more shares of NYXH or EMBC? 93.8% of Embecta shares are held by institutional investors. 17.1% of Nyxoah shares are held by company insiders. Comparatively, 0.4% of Embecta shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryEmbecta beats Nyxoah on 11 of the 17 factors compared between the two stocks. Get Nyxoah News Delivered to You Automatically Sign up to receive the latest news and ratings for NYXH and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NYXH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NYXH vs. The Competition Export to ExcelMetricNyxoahMEDICAL INFO SYS IndustryMedical SectorNASDAQ ExchangeMarket Cap$213.90M$2.06B$5.76B$9.84BDividend YieldN/AN/A3.95%4.02%P/E Ratio-2.7337.5831.3126.60Price / Sales43.7413.21461.30121.37Price / CashN/A52.2937.7659.36Price / Book2.566.5910.026.67Net Income-$64.10M-$63.67M$3.27B$265.59M7 Day Performance-1.10%3.23%3.17%3.42%1 Month Performance-12.41%0.62%4.34%1.09%1 Year Performance-25.33%28.23%44.11%23.85% Nyxoah Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NYXHNyxoah2.2096 of 5 stars$6.28+1.8%$15.00+138.9%-24.3%$213.90M$4.89M-2.73110EMBCEmbecta4.7648 of 5 stars$14.26-0.8%$19.00+33.2%-0.1%$841.02M$1.12B9.972,100News CoveragePositive NewsAnalyst UpgradeTNDMTandem Diabetes Care4.6342 of 5 stars$12.11+1.5%$22.47+85.5%-73.1%$806.10M$940.20M-3.922,650Positive NewsAXGNAxoGen2.4729 of 5 stars$14.79-9.0%$26.00+75.8%+27.0%$748.16M$187.34M-147.89450News CoverageBBNXBeta Bionics1.5729 of 5 stars$17.45+2.3%$22.56+29.3%N/A$741.17M$65.12M0.00294SIBNSiBone4.2521 of 5 stars$16.05-2.1%$23.67+47.5%+0.7%$707.08M$167.18M-28.66350News CoveragePositive NewsBVSBioventus0.9017 of 5 stars$7.44-2.6%N/AN/A$631.67M$573.28M15.281,200AVNSAVANOS MEDICAL3.4303 of 5 stars$11.58-1.2%N/A-50.1%$543.37M$687.80M-1.152,227Positive NewsZIMVZimVie0.5079 of 5 stars$18.96+0.1%$17.75-6.4%+9.1%$534.41M$449.75M-27.091,770News CoverageKIDSOrthoPediatrics4.4191 of 5 stars$20.29+0.4%$34.14+68.3%-31.4%$506.49M$204.73M-11.34200Positive NewsTMCITreace Medical Concepts2.4462 of 5 stars$7.47-3.0%$9.83+31.6%+20.8%$486.43M$209.36M-9.46250Positive News Related Companies and Tools Related Companies Embecta Competitors Tandem Diabetes Care Competitors AxoGen Competitors Beta Bionics Competitors SiBone Competitors Bioventus Competitors AVANOS MEDICAL Competitors ZimVie Competitors OrthoPediatrics Competitors Treace Medical Concepts Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NYXH) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nyxoah SA Please log in to your account or sign up in order to add this asset to your watchlist. Share Nyxoah With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access